APGE Relative Valuation
APGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APGE is overvalued; if below, it's undervalued.
Historical Valuation
Apogee Therapeutics Inc (APGE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -12.60. The fair price of Apogee Therapeutics Inc (APGE) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：39.31
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.40
P/B
Median3y
3.06
Median5y
3.06
-8.48
FCF Yield
Median3y
-5.13
Median5y
-5.13
Competitors Valuation Multiple
The average P/S ratio for APGE's competitors is 31.80, providing a benchmark for relative valuation. Apogee Therapeutics Inc Corp (APGE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Apogee Therapeutics Inc (APGE) currently overvalued or undervalued?
What is Apogee Therapeutics Inc (APGE) fair value?
How does APGE's valuation metrics compare to the industry average?
What is the current P/B ratio for Apogee Therapeutics Inc (APGE) as of Jul 20 2025?
What is the current FCF Yield for Apogee Therapeutics Inc (APGE) as of Jul 20 2025?
What is the current Forward P/E ratio for Apogee Therapeutics Inc (APGE) as of Jul 20 2025?